Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
NCT05547737 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2022-09-21
Summary
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world
Conditions
Interventions
- DRUG
-
Camrelizumab
Cross - line treatment of Camrelizumab in non-small cell lung cancer
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
collaborator INDUSTRY -
Henan Cancer Hospital
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-21
- Primary Completion
- 2025-09-21
- Completion
- 2025-09-21
More Related Trials
-
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
NCT04453930 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer
NCT05965102 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
NCT04459078 ·Status: UNKNOWN ·Phase: PHASE2
-
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer
NCT03647111 ·Status: RECRUITING
-
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate
NCT04059874 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
NCT05117658 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
NCT05435274 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT05435248 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
NCT04586088 ·Status: UNKNOWN ·Phase: PHASE2
-
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
NCT05209256 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
NCT05430386 ·Status: UNKNOWN ·Phase: PHASE1
-
The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy
NCT04782622 ·Status: UNKNOWN
-
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
NCT06430437 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study
NCT04517526 ·Status: UNKNOWN ·Phase: PHASE2
-
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572 ·Status: RECRUITING ·Phase: PHASE2
-
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
NCT03646994 ·Status: RECRUITING
-
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
NCT05466149 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
NCT01850147 ·Status: UNKNOWN ·Phase: PHASE2
-
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
NCT06436885 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
NCT04041011 ·Status: COMPLETED ·Phase: PHASE1